Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
General Biomarker Recommendations for Lymphoma.
Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, Kostakoglu L. Rimsza L, et al. Among authors: hsi e. J Natl Cancer Inst. 2016 Dec 16;108(12):djw250. doi: 10.1093/jnci/djw250. Print 2016 Dec. J Natl Cancer Inst. 2016. PMID: 27986882 Free PMC article.
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, Hsi ED. Sweetenham JW, et al. Among authors: hsi ed. Ann Oncol. 2010 Jun;21(6):1196-1202. doi: 10.1093/annonc/mdp460. Epub 2009 Oct 29. Ann Oncol. 2010. PMID: 19875761 Free PMC article.
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.
Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Weller EA, Melnick A, Reed JC, Horning SJ, Gascoyne RD. Winter JN, et al. Among authors: hsi ed. Clin Cancer Res. 2010 Apr 15;16(8):2435-42. doi: 10.1158/1078-0432.CCR-09-1219. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371683 Free PMC article. Clinical Trial.
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD; Cancer and Leukemia Group B. Straus DJ, et al. Among authors: hsi ed. Blood. 2011 May 19;117(20):5314-20. doi: 10.1182/blood-2010-10-314260. Epub 2011 Feb 25. Blood. 2011. PMID: 21355087 Free PMC article. Clinical Trial.
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Czuczman MS, et al. Among authors: hsi ed. Ann Oncol. 2012 Sep;23(9):2356-2362. doi: 10.1093/annonc/mdr620. Epub 2012 Feb 22. Ann Oncol. 2012. PMID: 22357442 Free PMC article. Clinical Trial.
507 results